BRPI0517398B8 - proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição - Google Patents

proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição

Info

Publication number
BRPI0517398B8
BRPI0517398B8 BRPI0517398A BRPI0517398A BRPI0517398B8 BR PI0517398 B8 BRPI0517398 B8 BR PI0517398B8 BR PI0517398 A BRPI0517398 A BR PI0517398A BR PI0517398 A BRPI0517398 A BR PI0517398A BR PI0517398 B8 BRPI0517398 B8 BR PI0517398B8
Authority
BR
Brazil
Prior art keywords
jak2
sirna
variant
absence
vitro
Prior art date
Application number
BRPI0517398A
Other languages
English (en)
Portuguese (pt)
Inventor
James Chloé
Le Couedic Jean-Pierre
Casadevall Nicole
Ugo Valérie
Vainchenker William
Original Assignee
Hopitaux Paris Assist Publique
Roussy Inst Gustave
Inst Nat Sante Rech Med
Univ Paris Sud
Univ De Versailles St Quentin En Yvelines
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34953071&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0517398(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hopitaux Paris Assist Publique, Roussy Inst Gustave, Inst Nat Sante Rech Med, Univ Paris Sud, Univ De Versailles St Quentin En Yvelines filed Critical Hopitaux Paris Assist Publique
Publication of BRPI0517398A publication Critical patent/BRPI0517398A/pt
Publication of BRPI0517398B1 publication Critical patent/BRPI0517398B1/pt
Publication of BRPI0517398B8 publication Critical patent/BRPI0517398B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57595—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
BRPI0517398A 2004-10-27 2005-10-26 proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição BRPI0517398B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR0411480 2004-10-27
FR0411480A FR2877013A1 (fr) 2004-10-27 2004-10-27 Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
PCT/EP2005/055586 WO2006045827A1 (fr) 2004-10-27 2005-10-26 Identification d'une mutation de jak2 impliquée dans la polyglobulie de vaquez

Publications (3)

Publication Number Publication Date
BRPI0517398A BRPI0517398A (pt) 2008-10-14
BRPI0517398B1 BRPI0517398B1 (pt) 2021-03-02
BRPI0517398B8 true BRPI0517398B8 (pt) 2021-05-25

Family

ID=34953071

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0517398A BRPI0517398B8 (pt) 2004-10-27 2005-10-26 proteína isolada jak2, sequência nucleotídica, vetor de clonagem e/ou de expressão viral, sondas ou iniciadores, oligonucleotídeo, métodos ex vivo ou in vitro para determinar a presença ou a ausência da variante g1849t do gene jak2, anticorpo monoclonal, hibridoma, kit, sirna, processos in vitro permitindo determinar a inibição específica de jak2 v617f, de triagem, utilização de sirna, e, composição

Country Status (20)

Country Link
US (9) US7781199B2 (enExample)
EP (2) EP1895000A1 (enExample)
JP (3) JP5090171B2 (enExample)
KR (1) KR101203003B1 (enExample)
CN (1) CN101072870B (enExample)
AT (1) ATE382082T1 (enExample)
AU (1) AU2005298636B2 (enExample)
BR (1) BRPI0517398B8 (enExample)
CA (3) CA2647086C (enExample)
DE (1) DE602005004008T2 (enExample)
DK (1) DK1692281T3 (enExample)
ES (1) ES2296229T3 (enExample)
FR (1) FR2877013A1 (enExample)
IL (1) IL182761A0 (enExample)
MX (1) MX2007005174A (enExample)
PL (1) PL1692281T3 (enExample)
PT (1) PT1692281E (enExample)
SI (1) SI1692281T1 (enExample)
WO (1) WO2006045827A1 (enExample)
ZA (1) ZA200703433B (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
CN100497657C (zh) * 2006-09-27 2009-06-10 北京大学人民医院 检测JAK2V617F突变的方法及其专用引物与TaqMan-MGB探针
US20080153097A1 (en) * 2006-11-15 2008-06-26 Eragen Biosciences, Inc. Methods and kits for detecting jak2 nucleic acid
US8367078B2 (en) * 2007-06-06 2013-02-05 University Of Florida Research Foundation, Inc. Kinase inhibitor compounds
EP2119796B1 (en) * 2007-07-13 2014-01-15 ARKRAY, Inc. Probe for detecting mutation in jak2 gene and use thereof
GB0820631D0 (en) * 2008-11-11 2008-12-17 London School Hygiene & Tropical Medicine Vectors
EP2272978B1 (en) 2009-07-10 2012-04-18 Biotrin International Limited Highly sensitive rapid isothermal method for the detection of point mutations and SNPs
WO2011067373A1 (fr) * 2009-12-04 2011-06-09 Assistance Publique - Hopitaux De Paris Methode de detection d'une polyglobulie chez un chien
CA2789186A1 (en) * 2010-02-10 2011-08-18 Genon Biotechnologies Oy Dual activity kinase domains and uses thereof
US20120021413A1 (en) * 2010-04-30 2012-01-26 Arkray, Inc. Method for Detecting Mutation in Exon 12 of JAK2 Gene, and Nucleic Acid Probe and Kit Therefor
JP6076901B2 (ja) * 2010-07-16 2017-02-15 スティヒティング フェーユーエムセー 被験者の血液サンプル中の疾患マーカーの存在の分析方法
SG193539A1 (en) 2011-03-18 2013-10-30 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek En Patientenzorg A method of analysing a blood sample of a subject for the presence of a disease marker
JP2013017395A (ja) * 2011-07-07 2013-01-31 Toyobo Co Ltd 骨髄増殖性疾患に関する遺伝子変異を検出するためのプローブおよび該プローブを用いた遺伝子変異の検出方法
GB201116876D0 (en) * 2011-09-30 2011-11-16 Epistem Ltd Mutational analysis of JAK2
CN103243153B (zh) * 2012-02-10 2014-11-05 复旦大学附属华山医院 Jak2 v617f突变的检测应用
WO2014068072A1 (en) 2012-10-31 2014-05-08 Institut Gustave-Roussy Identification, assessment and therapy of essential thrombocythemia with resistance to jak2 inhibitors
US9523084B2 (en) 2012-11-08 2016-12-20 Centre National De La Recherche Scientifique (Cnrs) Phosphodeoxyribosyl transferase mutant enzymes and uses thereof
CA2890658A1 (en) 2012-11-09 2014-05-15 The Johns Hopkins University A genetic assay to determine prognosis in polycythemia vera patients
PT3456333T (pt) 2012-12-07 2020-06-01 Geron Corp Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
SG11201509556TA (en) 2013-05-16 2015-12-30 Mobelisk Llc Modular tablet case
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
WO2016168612A1 (en) * 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
US10519509B2 (en) 2015-04-23 2019-12-31 Quest Diagnostics Investments Incorporated Methods and compositions for the detection of CALR mutations in myeloproliferative diseases
WO2017024171A1 (en) * 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
CN105441573A (zh) * 2016-01-11 2016-03-30 武汉海吉力生物科技有限公司 用于检测人类jak2基因v617f突变的引物、探针及试剂盒
CN109803674A (zh) * 2016-06-10 2019-05-24 Io生物技术公司 Calr和jak2疫苗组合物
EP3658156B1 (en) 2017-07-28 2026-03-25 Geron Corporation Telomerase inhibitor for use in treating a myelodysplastic syndrome
CN113631719A (zh) 2018-11-29 2021-11-09 美国杰龙生物医药公司 治疗骨髓增生异常综合征的方法
EP4061405A1 (en) 2019-11-18 2022-09-28 Janssen Biotech, Inc. Vaccines based on mutant calr and jak2 and their uses
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors
WO2026136827A1 (en) * 2024-12-20 2026-06-25 Incyte Corporation Treatment of clonal hematopoietic disorders using kinase inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6582908B2 (en) * 1990-12-06 2003-06-24 Affymetrix, Inc. Oligonucleotides
US5728536A (en) * 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
WO1995011995A1 (en) 1993-10-26 1995-05-04 Affymax Technologies N.V. Arrays of nucleic acid probes on biological chips
US5753441A (en) * 1994-08-12 1998-05-19 Myriad Genetics, Inc. 170-linked breast and ovarian cancer susceptibility gene
US5747282A (en) * 1994-08-12 1998-05-05 Myraid Genetics, Inc. 17Q-linked breast and ovarian cancer susceptibility gene
WO1997003358A1 (en) * 1995-07-07 1997-01-30 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method of identifying inhibitors of the jak-stat signal transduction pathway
US5914393A (en) * 1995-12-05 1999-06-22 Incyte Pharmaceuticals, Inc. Human Jak2 kinase
FI104718B (fi) * 1998-06-18 2000-03-31 Orion Yhtymae Oyj [[4-(2-atsido-3-metyyli-5-oksotetrahydrofuran-2-yyli)fenyyli]hydratsono]propaanidinitriili käytettäväksi referenssiaineena levosimendaanierien analyysissä
US6821724B1 (en) * 1998-09-17 2004-11-23 Affymetrix, Inc. Methods of genetic analysis using nucleic acid arrays
EP1056889B1 (en) 1998-09-25 2007-06-27 Massachusetts Institute Of Technology Methods related to genotyping and dna analysis
WO2001079555A2 (en) * 2000-04-14 2001-10-25 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
IL153426A0 (en) * 2000-06-30 2003-07-06 Pfizer Method of treating peripheral vascular diseases, peripheral neuropathies, and autonomic neuropathies
US20030012788A1 (en) * 2000-07-27 2003-01-16 Jean-Christophe Renauld Method for influencing kinase pathways with IL-22
US20020090622A1 (en) 2000-08-23 2002-07-11 Monisola Adeokun Chemical compounds
US20050235375A1 (en) * 2001-06-22 2005-10-20 Wenqiong Chen Transcription factors of cereals
AU2003299467A1 (en) 2002-05-03 2004-08-10 Gene Logic, Inc. Canine gene microarrays
CA2491637A1 (en) * 2002-07-03 2004-01-15 The Trustees Of Columbia University In The City Of New York Methods for identifying modulators of mda-7 mediated apoptosis
US7537891B2 (en) * 2002-08-27 2009-05-26 Bristol-Myers Squibb Company Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in breast cells
EP1572957A4 (en) * 2002-08-27 2007-10-10 Bristol Myers Squibb Pharma Co IDENTIFICATION OF POLYNUCLEOTIDES FOR PREDICTING THE ACTIVITY OF COMPOUNDS INTERACTING WITH AND / OR MODULATING TYROSINE KINASE PROTEINS AND / OR TYROSINE KINASE PROTEIN PATHWAYS IN MAMMARY CELLS
US20060019284A1 (en) * 2004-06-30 2006-01-26 Fei Huang Identification of polynucleotides for predicting activity of compounds that interact with and/or modulate protein tyrosine kinases and/or protein tyrosine kinase pathways in lung cancer cells
FR2877013A1 (fr) * 2004-10-27 2006-04-28 Assist Publ Hopitaux De Paris Indentification d'une mutation de jak2 impliquee dans la polyglobulie de vaquez
US7514229B2 (en) * 2005-09-29 2009-04-07 The Board Of Trustees Of The Leland Stanford Junior University Methods for diagnosing and evaluating treatment of blood disorders
US20070248961A1 (en) * 2006-04-20 2007-10-25 Maher Albitar Methods for detecting mutations in JAK2 nucleic acid
EP2525651A4 (en) * 2010-01-22 2013-12-11 Chromatin Inc NEW CENTROMERE AND METHOD FOR THEIR USE

Also Published As

Publication number Publication date
PT1692281E (pt) 2008-02-06
US7429456B2 (en) 2008-09-30
US8637235B2 (en) 2014-01-28
DE602005004008T2 (de) 2009-02-12
JP2009278982A (ja) 2009-12-03
BRPI0517398B1 (pt) 2021-03-02
US20190323007A1 (en) 2019-10-24
ES2296229T3 (es) 2008-04-16
HK1094974A1 (zh) 2007-04-20
DK1692281T3 (da) 2008-05-13
JP6103691B2 (ja) 2017-03-29
IL182761A0 (en) 2007-07-24
MX2007005174A (es) 2007-10-10
EP1692281B8 (fr) 2008-02-13
KR20070104338A (ko) 2007-10-25
US20150051263A2 (en) 2015-02-19
AU2005298636A1 (en) 2006-05-04
US20080076135A1 (en) 2008-03-27
JP5290884B2 (ja) 2013-09-18
JP5090171B2 (ja) 2012-12-05
CA2647086C (fr) 2012-09-18
US10364430B2 (en) 2019-07-30
US20090162849A1 (en) 2009-06-25
EP1692281A1 (fr) 2006-08-23
EP1895000A1 (fr) 2008-03-05
US11162100B2 (en) 2021-11-02
ZA200703433B (en) 2008-08-27
US20220042016A1 (en) 2022-02-10
AU2005298636B2 (en) 2009-11-26
US7781199B2 (en) 2010-08-24
JP2008517613A (ja) 2008-05-29
JP2013135673A (ja) 2013-07-11
US20060288432A1 (en) 2006-12-21
CN101072870A (zh) 2007-11-14
FR2877013A1 (fr) 2006-04-28
US20130189683A1 (en) 2013-07-25
US20200140863A1 (en) 2020-05-07
US8466338B2 (en) 2013-06-18
PL1692281T3 (pl) 2008-06-30
US8852931B2 (en) 2014-10-07
US10563200B2 (en) 2020-02-18
EP1692281B1 (fr) 2007-12-26
CA2754028A1 (fr) 2006-05-04
SI1692281T1 (sl) 2008-04-30
DE602005004008D1 (de) 2008-02-07
ATE382082T1 (de) 2008-01-15
KR101203003B1 (ko) 2012-11-21
CA2585062C (fr) 2012-11-20
US20140249204A1 (en) 2014-09-04
CA2585062A1 (fr) 2006-05-04
BRPI0517398A (pt) 2008-10-14
US20120066776A1 (en) 2012-03-15
WO2006045827A1 (fr) 2006-05-04
CA2647086A1 (fr) 2006-05-04
CN101072870B (zh) 2013-01-30

Similar Documents

Publication Publication Date Title
BRPI0517398A (pt) proteìna isolada, seqüência nucleotìdica, vetor, célula de mamìfero, animal transgênico não humano, sondas ou iniciadores, métodos para determinar a presença ou a ausência da variante g1849t do gene jak2, para detectar a presença ou a ausência da variante jak2 v617f, anticorpo monoclonal, hibridoma, kit, sirna, processos permitindo determinar a inibição especìfica de jak2 v617f, de triagem, para a identificação de candidatos medicamentos, utilização de sirna, e, composição
Xu et al. MiR-497 downregulation contributes to the malignancy of pancreatic cancer and associates with a poor prognosis
Torregrosa-Muñumer et al. PrimPol is required for replication reinitiation after mtDNA damage
Hong et al. FNDC3B circular RNA promotes the migration and invasion of gastric cancer cells via the regulation of E‐cadherin and CD44 expression
Shammas et al. Telomerase inhibition by siRNA causes senescence and apoptosis in Barrett's adenocarcinoma cells: mechanism and therapeutic potential
Wood et al. DNA polymerase θ (POLQ), double-strand break repair, and cancer
Yang et al. Aberrant expression of miR‐29b‐3p influences heart development and cardiomyocyte proliferation by targeting NOTCH2
Lin et al. MicroRNA-128 inhibits proliferation and invasion of glioma cells by targeting COX-2
JP2011511949A5 (enExample)
Seubert et al. Tetraspanin CD 63 acts as a pro‐metastatic factor via β‐catenin stabilization
Okura et al. Functional expression of organic cation/carnitine transporter 2 (OCTN2/SLC22A5) in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model
Stapelberg et al. Indoleamine-2, 3-dioxygenase elevated in tumor-initiating cells is suppressed by mitocans
Rebollo et al. ESM-1 siRNA knockdown decreased migration and expression of CXCL3 in prostate cancer cells
Akbari et al. Different organization of base excision repair of uracil in DNA in nuclei and mitochondria and selective upregulation of mitochondrial uracil-DNA glycosylase after oxidative stress
KR20180044617A (ko) Uhrf1 및 dnmt1을 포함하는 세포 노화 진단용 바이오마커 조성물
Pal et al. Augmented telomerase activity, reduced telomere length and the presence of alternative lengthening of telomere in renal cell carcinoma: plausible predictive and diagnostic markers
CN109069513A (zh) 用于治疗或预防肝癌的组合物
Khan et al. Gβ4γ1 as a modulator of M3 muscarinic receptor signalling and novel roles of Gβ1 subunits in the modulation of cellular signalling
Zhou et al. A conformational switch-based fluorescent biosensor for homogeneous detection of telomerase activity
Xi et al. A natural antisense transcript regulates acetylcholinesterase gene expression via epigenetic modification in Hepatocellular Carcinoma
Kim et al. DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling
Yoshimura et al. WRNIP1 controls the amount of PrimPol
US20190105340A1 (en) Methods and compositions for targeting vascular mimicry
Meeh et al. A gene expression classifier of node-positive colorectal cancer
Liu et al. Reversible proliferative arrest induced by rapid depletion of RNase MRP

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C12N 9/12 , C12Q 1/68 , G01N 33/53

Ipc: C12N 9/12 (2006.01), C12Q 1/68 (2006.01), G01N 33/

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/03/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/10/2005 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) ; INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) ; UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES (FR) ; INSTITUT GUSTAVE-ROUSSY (FR) ; UNIVERSITE PARIS-SACLAY (FR)